Skip to main content
S&P 5007,759.41-0.54%DOW51,129.61-0.10%NASDAQ27,194.18-1.25%BTC$80,581.00-3.21%ETH$2,413.00-5.58%GOLD$4,153.20+0.30%OIL$92.14+4.37%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRTS

Alpha Tau Medical Ltd.

Healthcare · Biotechnology

$14.25

Down-$0.47 (-3.30%)

Updated Oct 8, 2026, 5:59 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
418.18M
P/E ratio
-10.28
Dividend yield
0.00%
52-week range
$6.10 – $15.79
Volume
466.37K
Avg. volume
110.09K

Price performance · DRTS

DRTS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

DRTS closed at $14.25 after 21 trading sessions, down 0.14% for the selected period.

Last close
$14.25
Period change
-0.14%
Period low
$14.25
Period high
$15.50
Daily close
View OHLC price history
DRTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$14.27$14.44$14.10$14.25466.37K
Oct 6, 2026$14.975$15.02$14.40$14.48427.52K
Oct 5, 2026$14.85$15.0399$14.68$14.89342.44K
Oct 2, 2026$14.73$14.91$14.64$14.77307.41K
Oct 1, 2026$14.74$14.97$14.3177$14.51379.97K
Sep 30, 2026$15.14$15.335$14.88$14.91369.27K
Sep 29, 2026$15.00$15.30$14.765$15.19513.93K
Sep 28, 2026$14.54$15.20$14.39$15.04397.84K
Sep 25, 2026$14.90$14.92$14.39$14.54435.37K
Sep 24, 2026$14.50$14.80$14.31$14.77468.68K
Sep 23, 2026$15.09$15.25$14.31$14.52727.07K
Sep 22, 2026$15.38$15.45$15.05$15.14360.47K
Sep 21, 2026$15.48$15.59$15.1001$15.50412.75K
Sep 18, 2026$15.60$15.625$15.10$15.24624.26K
Sep 17, 2026$15.15$15.79$15.01$15.49858.88K
Sep 16, 2026$14.88$15.20$14.73$15.04671.59K
Sep 15, 2026$14.30$15.00$14.20$14.87412.4K
Sep 14, 2026$14.11$14.8399$14.11$14.40388.02K
Sep 11, 2026$14.49$14.62$14.01$14.43410.4K
Sep 10, 2026$14.04$14.81$13.80$14.44457.19K
Sep 9, 2026$14.70$14.8399$14.27$14.27412.38K

Latest DRTS news

The latest Smart Investors Daily articles mentioning DRTS.

Stock researchCompany · Overview

DRTS research

Overview

Company profile and research snapshot.

Company profile

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
DRTS recent ratings
DateFirmRatingTarget
Sep 3, 2026BarclaysOverweight—
Aug 11, 2026HC Wainwright & Co.Buy—
Jul 22, 2026HC Wainwright & Co.Buy—
Jul 16, 2026HC Wainwright & Co.Buy—
Jun 4, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Alpha Tau to Participate in October Investor Conferences

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026. Event:Fall Focus: Barclays Biotech 1x1 DayFormat:1x1 MeetingsDate:Tuesday, October 6, 2026Location:New York, NY Event:Investment Generation ConferenceFormat:PresentationDate:Thursday, Octob

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By